GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
Lexaria Announces Results From Animal Study GLP-1-A26-1
Lexaria Updates Financial Position
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lexaria Receives USD$2.6 Million Tax Rebate Payment
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.